NMR studies of the interaction of cis-diamminedichloro-platinum(II) and corresponding hydrolysis products with adenosine phosphates

Ultrastructural localization of cisplatin in Ehrlich ascites tumor cells

The incorporation of cis-diammine Dichloro Platinum (II) (cisplatin) on the Ehrlich ascites carcinoma (EAT) cells has been studied in this paper. Ultrastructural study of cells treated 'in vivo' with cisplatin showed that a new treatment with this substance after fixation, blocks uranyl acetate staining with the consequent lack of heterochromatin contrast.

Influence of time and chloride ions on the interaction of cisplatin with human albumin in-vitro

The interaction of cis-dichlorodiammineplatinum (II) (cisplatin) with human serum albumin (HSA), dissolved in phosphate buffer with or without sodium chloride (0.1 M) has been examined at pH 7.4 and mu = 0.154. Equal volumes of cisplatin and HSA solutions were incubated at 37 degrees C for various times and filterable platinum concentrations versus time measured by flameless atomic absorption spectrophotometry. Binding kinetics differed depending on the buffer solutions used and on the time elapsing between cisplatin dissolution and outset of incubation with HSA. Experimental data were fitted to a theoretical equation used to calculate the number of nucleophilic sites per HSA molecule. Titrations of the HSA sulphydryl group content before and after incubation with a cisplatin solution were made, from which it was shown that the lone SH-group of the HSA macromolecule is involved in cisplatin binding. We also studied HSA's sensitivity towards denaturing agents when it was complexed with cisplatin. This sensitivity was decreased upon cisplatin binding. Also, the binding capacities of HSA and the HSA-Pt(II) complex to both tryptophan and warfarin were compared to determine the possible influence of cisplatin upon the binding to HSA of other drugs; this influence was negligible.